Laura J. van ‘t Veer, PhD, University of California San Francisco, San Francisco, CA, discusses updated outcome data from the MINDACT study (NCT00433589), a large prospective randomized trial enrolling over 6000 women with early-stage breast cancer and whose genomic risk (using the 70-gene signature) and their clinical risk were evaluated. Women at low clinical and genomic risk did not receive chemotherapy, whereas those at high clinical and genomic risk did receive such therapy. In patients with discordant risk results, either the genomic risk or the clinical risk was used to determine the use of chemotherapy. At the San Antonio Breast Cancer Symposium (SABCS) 2020, Prof. van’t Veer outlines updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age, and nodal status. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).